Opinion|Videos|April 18, 2025
Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
Panelists discuss how, PSMA PET imaging significantly enhances surgical decision-making in prostate cancer by precisely identifying tumor location, extent, and metastatic spread with superior sensitivity compared to conventional imaging. This molecular targeting enables more accurate surgical planning, improved patient selection for radical prostatectomy versus targeted approaches, and better identification of lymph node involvement, ultimately allowing for personalized treatment strategies that maximize oncological outcomes while minimizing unnecessary interventions.
Advertisement
Video content above is prompted by the following:
- Briefly discuss the role of PSMA PET imaging in assessing for biochemical recurrence and how imaging guides treatment decisions in this setting.
- What is your typical approach when monitoring for biochemical recurrence in this setting?
- When do you typically order PSMA PET imaging when monitoring for disease recurrence?
- How does PSMA PET imaging guide your treatment decisions in this setting?
- What do available data from pivotal trials demonstrate and how do these finding inform your decisions in this setting?
- LOCATE – Axumin (fluciclovine F18). Andriole et al. J Urol. 2019
- PSMA-BCR – Illuccix (gallium Ga68 gozetotide). Calais et al. J Nucl Med. 2018
- CONDOR – Pylarify (piflufolastat F18). Morris et al. Clin Cancer Res. 2021
- SPOTLIGHT – Posluma (flotufolastat F18). Jani et al. J Urol. 2023
Advertisement
Related to this article
Phase 3 TALAPRO-3 data support the FDA approval of talazoparib/enzalutamide in HRR gene-altered metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
3
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
4
Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC
5